(NASDAQ: CBIO) Crescent Biopharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 9.64%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.81%.
Crescent Biopharma's earnings in 2025 is -$29,486,227.On average, 3 Wall Street analysts forecast CBIO's earnings for 2025 to be -$3,194,339, with the lowest CBIO earnings forecast at -$5,162,568, and the highest CBIO earnings forecast at -$1,290,642. On average, 4 Wall Street analysts forecast CBIO's earnings for 2026 to be -$2,923,304, with the lowest CBIO earnings forecast at -$5,162,568, and the highest CBIO earnings forecast at -$1,935,963.
In 2027, CBIO is forecast to generate -$3,187,886 in earnings, with the lowest earnings forecast at -$4,517,247 and the highest earnings forecast at -$1,858,524.